Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
July 20, 2011
Overview: developmental toxicology: new directions
Dana Shuey, James H Kim
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
October 19, 2011
Developmental toxicology: new directions workshop: refining testing strategies and study designs
Kimberly C Brannen, Suzanne E Fenton, Deborah K Hansen, et al.
Toxicology and Applied Pharmacology
|
September 7, 2024
Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ consortium longer duration nonclinical to clinical translational database
Thomas M Monticello, David M Potter, Qihong Huang, et al.
Regulatory Toxicology and Pharmacology : RTP
|
December 31, 2022
FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations
David Ackley, Joanne Birkebak, Jorg Blumel, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 27, 2025
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Lise I Loberg, William R Proctor, Andrew D Burdick, et al.
Regulatory Toxicology and Pharmacology : RTP
|
September 10, 2020
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective
Vincent L Reynolds, Paul Butler, Matthew M Abernathy, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid Malignancies
Niu Shin, Yun-Long Li, Song Mei, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 17, 2016
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity
Ernst Ahlberg, Alexander Amberg, Lisa D Beilke, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
July 20, 2011
Overview: developmental toxicology: new directions
Dana Shuey, James H Kim
Birth Defects Research. Part B, Developmental and Reproductive Toxicology
|
October 19, 2011
Developmental toxicology: new directions workshop: refining testing strategies and study designs
Kimberly C Brannen, Suzanne E Fenton, Deborah K Hansen, et al.
Toxicology and Applied Pharmacology
|
September 7, 2024
Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ consortium longer duration nonclinical to clinical translational database
Thomas M Monticello, David M Potter, Qihong Huang, et al.
Regulatory Toxicology and Pharmacology : RTP
|
December 31, 2022
FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations
David Ackley, Joanne Birkebak, Jorg Blumel, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 27, 2025
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Lise I Loberg, William R Proctor, Andrew D Burdick, et al.
Regulatory Toxicology and Pharmacology : RTP
|
September 10, 2020
Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective
Vincent L Reynolds, Paul Butler, Matthew M Abernathy, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 12, 2017
INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid Malignancies
Niu Shin, Yun-Long Li, Song Mei, et al.
Regulatory Toxicology and Pharmacology : RTP
|
February 17, 2016
Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity
Ernst Ahlberg, Alexander Amberg, Lisa D Beilke, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2020
Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
Niu Shin, Matthew Stubbs, Holly Koblish, et al.
Page
of 1